BSE Live
Apr 13, 16:01Prev. Close
59.89
Open Price
57.12
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Bacil Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -0.05 | -0.19 | -0.04 | 0.07 | -0.01 | |
| Diluted EPS (Rs.) | -0.05 | -0.19 | -0.04 | 0.07 | -0.01 | |
| Cash EPS (Rs.) | -0.04 | -0.16 | -0.03 | 0.07 | -0.01 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 9.90 | 9.95 | 10.12 | 10.16 | 10.09 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 9.90 | 9.95 | 10.12 | 10.16 | 10.09 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.00 | 0.00 | 1.63 | 0.70 | 0.01 | |
| PBDIT/Share (Rs.) | -0.04 | -0.16 | -0.03 | 0.08 | -0.01 | |
| PBIT/Share (Rs.) | -0.05 | -0.17 | -0.03 | 0.08 | -0.01 | |
| PBT/Share (Rs.) | -0.05 | -0.17 | -0.03 | 0.08 | -0.01 | |
| Net Profit/Share (Rs.) | -0.05 | -0.17 | -0.04 | 0.07 | -0.01 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 0.00 | 0.00 | -1.94 | 11.46 | -103.09 | |
| PBIT Margin (%) | 0.00 | 0.00 | -2.01 | 11.46 | -103.09 | |
| PBT Margin (%) | 0.00 | 0.00 | -2.01 | 11.46 | -103.09 | |
| Net Profit Margin (%) | 0.00 | 0.00 | -2.20 | 9.69 | -103.09 | |
| Return on Networth / Equity (%) | -0.49 | -1.67 | -0.35 | 0.67 | -0.08 | |
| Return on Capital Employed (%) | -0.49 | -1.67 | -0.35 | 0.67 | -0.08 | |
| Return on Assets (%) | -0.48 | -1.65 | -0.33 | 0.63 | -0.08 | |
| Total Debt/Equity (X) | 0.02 | 0.01 | 0.00 | 0.05 | 0.01 | |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 15.33 | 6.54 | 0.08 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.06 | 5.83 | 2.63 | 2.43 | 2.80 | |
| Quick Ratio (X) | 3.06 | 5.83 | 2.63 | 1.44 | 2.80 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 1.18 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 3.39 | 0.84 | 3.05 | 4.21 | 1.51 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 2.87 | 9.14 | 271.68 | |
| EV/EBITDA (X) | -121.24 | -8.15 | -147.24 | 79.75 | -263.53 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 3.00 | 8.51 | 271.67 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.50 | 0.13 | 0.48 | 0.59 | 0.23 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 3.00 | 8.52 | 288.75 | |
| Earnings Yield | -0.01 | -0.13 | -0.01 | 0.01 | 0.00 |
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth